



Docket PHO-120

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:)

Dees et al.)

Serial No.: 09/817,448)

Filed: March 26, 2001)

For: Intracorporeal Medicaments For High
Energy Phototherapeutic Treatment
Of Disease)

Examiner: G. Gabel)

Art Unit: 1641)

I hereby certify that this correspondence
is being deposited with the United States
Postal Service as first class mail in an
envelope addressed to:

Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450, on 3/18/04

Shannon Wallace

Date: March 18, 2004

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.97, Applicant hereby calls the Examiner's attention to documents listed on the attached form PTO/SB/08A which documents may be material to the examination of this application. A copy of each reference is included herewith. These references are cited in the accompanying amendment.

No interference should be drawn that any apparatus disclosed is equivalent to the subject invention.

The citation of the above discussed documents is not to be construed as an assertion that more pertinent art could not possibly be in existence. Citation of any document herein is not to be construed as an admission that any subject matter disclosed in the document is necessarily within the inventive field of endeavor, that any disclosure is necessarily prior in time to a particular date which may be relevant to the instant patent application, and/or that any disclosure is otherwise necessarily prior art with respect to the instant invention.

03/24/2004 WABDELRI 00000047 09817448

03 FC:1806


180.00 OP

Applicant also respectfully reserves the right to later set forth how the instant invention is distinguished over the disclosure of any document or other art, including the disclosure of those documents discussed herein, that may be cited by the Examiner in rejecting a claim in the instant patent application.

A fee of \$180.00 is being submitted herewith. If any further fee is due, please charge our deposit account no. 50-1039.

Respectfully submitted,

Dated: *March 18, 2004*


Mark J. Murphy
Registration No. 34,225

COOK, ALEX, McFARRON, MANZO,
CUMMINGS & MEHLER, LTD.
200 West Adams Street, Suite 2850
Chicago, Illinois 60606
(312) 236-8500



PTO/SB/08B (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 09/817,448

Filing Date March 26, 2001

First Named Inventor Dees et al.

Art Unit 1641

Examiner Name G. Gabel

Attorney Docket Number PHO-120

Sheet

2

of

2

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	CRC Handbook of Chemistry and Physics, 59th Edition 1978-1979, THE ELEMENT, pages B-24 - B-30.	
	4	Handbook of Health Physics and Radiological Health, Third Edition 1998. COMMONLY USED UNITS, SIGNS, SYMBOLS, CONVERSION FACTORS AND CONSTANTS, page 2-31.	
	5	Squibb (1977) Robengatope, Rose Benal Sodium ROBENGATOPE page J3-381C	
	6	The Merck Index Twelfth Edition 1996, ROSAPROSTOL page 1422.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.